杨飞

【摘要】 目的：分析长春瑞滨联合顺铂治疗阿霉素耐药的晚期乳腺癌的临床效果，为阿霉素耐药的晚期乳腺癌的临床治疗提供科学参考依据。方法：选取2012年1月-2013年12月本院收治的阿霉素耐药的晚期乳腺癌患者100例作为研究对象，将其随机分为观察组与对照组，各50例。观察组采用长春瑞滨联合顺铂治疗，对照组采用吉西他滨联合顺铂治疗，比较两组的近期疗效、远期疗效、安全性与不良反应。结果：两组患者的近期疗效比较，差异无统计学意义（P>0.05）；观察组无进展生存期和总生存时间均明显优于对照组（P<0.05）；观察组不良反应发生率均显著低于对照组（P<0.05）。结论：长春瑞滨联合顺铂与吉他西滨联合顺铂在治疗阿霉素耐药的晚期乳腺癌的近期疗效相似，但长春瑞滨联合顺铂的远期疗效更加显著且安全性更高，值得在临床中推广使用。

【关键词】 长春瑞滨； 顺铂； 阿霉素耐药； 晚期乳腺癌

Study on the Effect of Vinorelbine Combined with Cisplatin in the Treatment of Adriamycin Resistant Advanced Breast Cancer/YANG Fei.//Medical Innovation of China，2017，14（27）：038-041

【Abstract】 Objective：To analyze the clinical effect of Vinorelbine combined with Cisplatin in the treatment of adriamycin resistant advanced breast cancer，so as to provide a scientific basis for the clinical treatment of adriamycin resistant advanced breast cancer.Method：100 cases of adriamycin resistant advanced breast cancer in our hospital from January 2012 to December 2013 were selected as the research objects，they were randomly divided into the observation group and the control group，50 cases in each group.The observation group was treated with Vinorelbine combined with Cisplatin，and the control group was treated with Gemcitabine combined with Cisplatin.The short-term efficacy，long-term efficacy，safety and adverse reactions were compared of two groups.Result：The short-term efficacy were compared of two groups，the difference was not statistically significant（P>0.05），the progression free survival and overall survival of the observation group were significantly better than those of the control group（P<0.05），the adverse reactions of the observation group were significantly lower than those of the control group（P<0.05）.Conclusion：Vinorelbine combined with Cisplatin and Gemcitabine combined with Cisplatin has similar therapeutic effect in the treatment of adriamycin resistant advanced breast cancer，but the long-term efficacy of Vinorelbine combined with Cisplatin is more significant and higher safety，and is worthy of promotion in clinical use.

【Key words】 Vinorelbine； Cisplatin； Adriamycin resistance； Advanced breast cancer

First-authors address：The Affiliated Huaian Hospital of Xuzhou Medical University，Huaian 223002，China

doi：10.3969/j.issn.1674-4985.2017.27.011

乳腺癌是一種常见的女性恶性肿瘤，具有较高的生物恶性，随着近些年女性工作压力和生活环境的变化，该病的发生率呈逐年增长的趋势，对女性的健康造成了严重的威胁[1]。乳腺癌临床常用的治疗方法为手术治疗、化疗、放疗、理疗等方案，但由于该病早期无明显症状，一旦患者出现明显体征，多发展至中晚期，错过了最佳手术时期[2-3]。化疗是目前晚期乳腺癌比较有效的治疗措施，但患者易对化疗药物产生耐药性，产生耐药性之后的治疗药物选择空间较小，因此复发率和转移率较高[4]。因此，笔者主要针对长春瑞滨联合顺铂治疗阿霉素耐药的晚期乳腺癌的临床疗效展开分析，现报道如下。endprint

1 资料与方法

1.1 一般资料 选取2012年1月-2013年12月本院收治的阿霉素耐药的晚期乳腺癌患者100例作为研究对象，纳入标准：（1）经病理组织检查确诊为乳腺癌且临床分期为晚期。（2……